CA2178811A1 - Oligonucleotides anti-hbv - Google Patents

Oligonucleotides anti-hbv

Info

Publication number
CA2178811A1
CA2178811A1 CA002178811A CA2178811A CA2178811A1 CA 2178811 A1 CA2178811 A1 CA 2178811A1 CA 002178811 A CA002178811 A CA 002178811A CA 2178811 A CA2178811 A CA 2178811A CA 2178811 A1 CA2178811 A1 CA 2178811A1
Authority
CA
Canada
Prior art keywords
seq
cjp
oligo
hbv
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002178811A
Other languages
English (en)
Inventor
Leslie R. Coney
Catherine J. Pachuk
Kyonggeun Yoon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apollon Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2178811A1 publication Critical patent/CA2178811A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Méthodes et compositions inhibant la réplication virale. Il est, en particulier, possible d'obtenir l'arrêt total et irréversible de la réplication du virus de l'hépatite B (HBV) en introduisant dans une cellule cible un oligonucléotide complémentaire du brin DR2 plus du HBV et les nucléotides 5' et 3' adjacents.
CA002178811A 1993-12-23 1994-12-01 Oligonucleotides anti-hbv Abandoned CA2178811A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17253893A 1993-12-23 1993-12-23
US172,538 1993-12-23

Publications (1)

Publication Number Publication Date
CA2178811A1 true CA2178811A1 (fr) 1995-06-29

Family

ID=22628136

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002178811A Abandoned CA2178811A1 (fr) 1993-12-23 1994-12-01 Oligonucleotides anti-hbv

Country Status (4)

Country Link
EP (1) EP0751949A4 (fr)
JP (1) JPH09507062A (fr)
CA (1) CA2178811A1 (fr)
WO (1) WO1995017414A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856459A (en) * 1995-06-06 1999-01-05 Hybridon, Inc. Oligonucleotides specific for hepatitis B virus
EP1544311B1 (fr) * 2003-12-16 2009-11-18 Bio-Rad Pasteur Oligonucléotides pour la détection du virus de l'hépatite B
RS61447B1 (sr) * 2011-04-21 2021-03-31 Glaxo Group Ltd Modulacija ekspresije virusa hepatitisa b (hbv)
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
EP3749318A4 (fr) * 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC Raltitrexed gamma-polyglutamaté et utilisations associées

Also Published As

Publication number Publication date
WO1995017414A1 (fr) 1995-06-29
JPH09507062A (ja) 1997-07-15
EP0751949A1 (fr) 1997-01-08
EP0751949A4 (fr) 1997-08-20

Similar Documents

Publication Publication Date Title
JP4062365B2 (ja) 短い外部ガイド配列
JP3316216B2 (ja) 安定化外部ガイド配列
US5985662A (en) Antisense inhibition of hepatitis B virus replication
AU662304B2 (en) DNA construct for providing RNA therapy
US6057153A (en) Stabilized external guide sequences
US6849726B2 (en) Non-nucleotide containing RNA
US20030148985A1 (en) Methods and reagents for the inhibition of hepatitis B virus replication
US5610050A (en) Methods of preventing viral replication
CA2246503A1 (fr) Activateurs de rnase l et oligonucleotides antisens efficaces dans le traitement des infections a rsv
WO1995030746A1 (fr) Inhibition par oligonucleotides antisens du virus de l'hepatite c
JP2001525192A (ja) Ｃ型肝炎ウイルス関連疾患を治療する組成物及び方法
AU2006279454A1 (en) Chemically modified short interfering nucleic acid molecules that mediate rna interference
US6037463A (en) Enzymatic RNA molecules that cleave mutant N-RAS
EP1019497A1 (fr) Ribozymes en tete de marteau a fonction de clivage etendue
KR20100060018A (ko) 작은 간섭 ｒｎａ 및 이를 포함하는 ｂ형 간염 바이러스 치료용 약학 조성물
RU2418068C2 (ru) Молекулы химически модифицированной короткой интерферирующей нуклеиновой кислоты, которые опосредуют интерференцию рнк
CA2178811A1 (fr) Oligonucleotides anti-hbv
MX2008002369A (es) Moleculas cortas de acidos nucleicos de interferencia quimicamente modificadas que actuan de mediadoras de la interferencia del acido ribonucleico.
EP4077668A1 (fr) Utilisation d'inhibiteurs de scamp3 pour traiter une infection par le virus de l'hépatite b
WO2000004141A2 (fr) Utilisation de molecules d'acide nucleique comme agents antiviraux
US20230193263A1 (en) Use of sbds inhibitors for treating hepatitis b virus infection
EP4077671A1 (fr) Utilisation d'inhibiteurs de saraf pour traiter une infection par le virus de l'hépatite b
CN101208438A (zh) 使用双链核糖核酸治疗炎性疾病的方法
WO2000039146A1 (fr) Miniribozymes actifs a des concentrations d'ions magnesium faibles
JPH0977670A (ja) 抗ウイルス剤

Legal Events

Date Code Title Description
FZDE Dead